LYMA's US Conquest: How Science and Starpower Forged a Beauty Empire

NEW YORK, NY – April 06, 2026 – One year after its disruptive entry into the United States with the LYMA Laser PRO, British MedTech firm LYMA is escalating its American campaign. The company today announced a significant expansion, signaling its intent to deepen its roots in a market that has quickly become its most vital. The move includes a dedicated US e-commerce platform, new retail partnerships including a summer launch with Bloomingdale's, and a push into professional medical channels, all built on the back of staggering financial growth and unprecedented clinical validation.

This expansion is not just a strategic next step; it's a victory lap. The female-founded company reported a record-breaking 2025, with revenues hitting $48 million and an EBITDA of $7 million. The US, a market it entered only twelve months ago, now accounts for over 70% of its global sales. This dominance is accelerating, with direct-to-consumer sales in the first quarter of 2026 tripling year-over-year, cementing LYMA's transition from a promising British brand to a formidable force in the global technology of skin health.

A Financial Powerhouse Fueled by US Demand

The financial figures paint a clear picture of a brand that has captured the American consumer's imagination—and wallet. The initial launch of the nearly $6,000 Laser PRO in April 2025 was met with a waitlist of over 16,000 people, representing a potential demand exceeding $100 million. This fervor translated into a 130% increase in direct-to-consumer sales in the first six months alone.

LYMA's success is occurring within a booming, multi-billion dollar industry. The US market for home-use beauty devices was valued at over $9 billion in 2025, with North America commanding more than 40% of the global at-home therapeutic beauty device market. Within this competitive landscape, consumers are increasingly gravitating towards devices backed by tangible results and regulatory approval—a niche LYMA has expertly cultivated.

To capitalize on this momentum, the company's new US-centric infrastructure is designed to eliminate friction for its largest customer base. The new standalone website will feature USD pricing, faster fulfillment, and a dedicated US concierge team. Crucially, LYMA is introducing flexible payment plans and, for the first time, allowing eligible customers to use Health Savings Account (HSA) and Flexible Spending Account (FSA) funds, a savvy move that frames the high-end device as a legitimate health and wellness investment.

"A year ago, we launched the LYMA Laser PRO in the US with the most rigorous science ever published behind an at-home device, and the most extraordinary waitlist we had ever seen," said Lucy Goff, CEO and Founder of LYMA. "The US has not just adopted LYMA; it has made it its own. We are only at the beginning of what we intend to build in the US."

The Science Behind the Glow

While celebrity endorsements provide the glamour, LYMA's core differentiator lies in its formidable scientific credentials, which set it apart in a crowded market. The LYMA Laser PRO is not just another light-based gadget; it is an FDA 510(k) cleared medical device (K243330), a regulatory milestone achieved in February 2025 that attests to its safety and efficacy.

This clearance is supported by a wealth of clinical data, most notably a landmark study published in the prestigious Aesthetic Surgery Journal Open Forum. The peer-reviewed research provided the first evidence of multi-gene longevity activation from a consumer device. The results are striking: RNA sequencing analysis showed the LYMA Laser activated 45 different genes related to skin renewal and repair, compared to just a single gene activated by a standard LED device.

The study's key findings read like a wish list for skin rejuvenation. It documented a 103% increase in skin elasticity in just 30 days—a figure the company claims is a clinical record for any at-home device. It also showed a 46% reduction in pigmentation over six weeks and a remarkable 40% complete wound healing in the test group, versus 0% in the control group. Furthermore, the device was shown to produce a six-fold increase in the expression of SIRT1, often dubbed the "longevity gene," and a 32-fold increase in TXNRD1, a gene critical for protecting cells against oxidative stress. With 38 global patents protecting its technology, LYMA has built a scientific fortress around its product.

Strategy, Starpower, and Strategic Partnerships

LYMA has masterfully blended its hard science with the soft power of influence. The device has become a staple in the routines of Hollywood's elite and public figures, from Gwyneth Paltrow and Kate Hudson to Martha Stewart. Academy Award-winner Carey Mulligan called it her "Oscars present to myself," noting it visibly reduced a scar, while Sienna Miller praised its ability to work "at a cellular level, not just on the surface." The endorsements extend to the highest echelons of the beauty industry, with master makeup artists like Pat McGrath and aestheticians like Joanna Czech integrating it into their practices.

This high-profile adoption is now being leveraged into a broader commercial strategy. The upcoming launch in Bloomingdale's marks a significant move into physical luxury retail, complementing existing online partnerships with retailers like Goop and Revolve. To spearhead this multi-channel growth, the company has made its first C-suite hire in the US, appointing Nicole Fein as US Growth Officer. Fein is tasked with expanding the B2B, wholesale, and distributor accounts.

Perhaps the most significant strategic move is the new physician referral program, launching first in New York. By creating formal partnership routes for plastic surgeons, dermatologists, and medical spa owners, LYMA is embedding its technology directly into the professional aesthetic ecosystem. This validates the device's clinical standing and creates a powerful new sales channel, endorsed by the very experts consumers trust most, including early champions like Dr. Jason Diamond and Dr. Dendy Engleman.

Beyond the Surface: A New Frontier in Holistic Wellness

Just as it solidifies its dominance in skin science, LYMA is already looking toward its next frontier: holistic health. The company has announced it will enter a completely new category next month with the launch of the world's first "four-dimensional gut formula."

While details remain under wraps, the move signals a strategic expansion from topical, external treatments to internal, systemic wellness. It's a pivot that taps directly into the growing consumer understanding that overall health, from the gut microbiome to cellular function, is intrinsically linked to appearance and longevity. This aligns with endorsements from figures like pioneering biohacker Dave Asprey, who has incorporated the Laser PRO into his own human optimization protocol. "If you're serious about changing how your skin looks—and feels—this is the future," Asprey states.

By branching into nutraceuticals, LYMA is positioning itself not just as a beauty device company, but as a comprehensive longevity and wellness brand. This diversification could open up vast new revenue streams and insulate it from competition in the device-only space, reflecting a future where the lines between beauty, health, and technology are increasingly blurred.